Blepharospasm

Introducing Neurolux™: Revolutionizing Relief for Migraine and Photophobia Sufferers with a Dual-Pair Solution

Retrieved on: 
Wednesday, December 13, 2023
Blepharospasm, Migraine, Health, Photophobia, Lens, Telescopic sight

An innovative solution for people who suffer from light sensitivity and migraines is finally here.

Key Points: 
  • An innovative solution for people who suffer from light sensitivity and migraines is finally here.
  • The first Neurolux™ pair, designed for daily use, offers consistent relief from light sensitivity, enhancing visual comfort, and reducing the frequency of migraine triggers.
  • The second pair, Neurolux™ Active Migraine, is crafted for times of intense symptoms, providing an extra layer of protection and soothing relief during severe migraine episodes.
  • "Migraines and photophobia can be debilitating, but we believe that relief should not be a luxury," said Dr. Marc Weinstein, CEO of Value Eyecare Network.

Merz Therapeutics Expands Business with New Nordics Affiliate

Retrieved on: 
Wednesday, June 28, 2023
Biotechnology, Pharmaceutical, Health, Neurotoxin, Blepharospasm, Desitin, Hypersalivation, Patient, Hemifacial spasm, Torticollis, Therapy, Merz, Pharmaceutical industry, Nordic

By taking the strategic decision to establish the new subsidiary in Stockholm, Merz Therapeutics is assuming full control of its business operations in the region, effectively replacing the previous distribution partner Desitin.

Key Points: 
  • By taking the strategic decision to establish the new subsidiary in Stockholm, Merz Therapeutics is assuming full control of its business operations in the region, effectively replacing the previous distribution partner Desitin.
  • By establishing Merz Therapeutics Nordics AB, the company aims to optimize its market presence, better serve patients and customers, and better capitalize on the region's market potential.
  • CEO of Merz Therapeutics, Stefan König, about the company's expansion in the Nordics: "Establishing our presence in the Nordics is a strategic move that will allow us to better serve our patients’ needs in the region.
  • Together, we embark on an exciting journey to enhance patient outcomes throughout Europe," says Marcus Gollub, Head of Region Europe at Merz Therapeutics.

Recommend Trusted Eye Care Brands to Protect Patient Safety During Eyedrop Recall Scare

Retrieved on: 
Wednesday, March 22, 2023
Blepharospasm, Telecanthus, Optometry, Woman, Cataract, Floater, Patient, Patient safety, Risk, Ophthalmology, OTC, FDA, Death, Safety, Pharmaceutical industry, Cosmetics, Dietary supplement

ROSENBERG, Texas, March 22, 2023 /PRNewswire/ -- Recently, new OTC eyedrop suppliers have emerged capitalizing on the large numbers of Dry Eye sufferers.

Key Points: 
  • ROSENBERG, Texas, March 22, 2023 /PRNewswire/ -- Recently, new OTC eyedrop suppliers have emerged capitalizing on the large numbers of Dry Eye sufferers.
  • One such product prompted a nation-wide recall as a result of multiple infections and even a death.
  • Recommend recognized branded artificial tears and eyelid cleansers that adhere to proper FDA safety guidelines.
  • Such treatment can be a shortcut to market without FDA guidelines or approval; without recognized clinical data; all of which leave open the question of efficacy, quality, and patient safety.

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Retrieved on: 
Friday, May 27, 2022
SIX Swiss Exchange, Glutamic acid, Nasdaq, Population, Food, PAM, Spasms, Glutamate (neurotransmitter), Psychosis, Patient, Therapy, Blepharospasm, Clinical trial, GABAB, Epilepsy, Neurodegeneration, LR, IND, ADX71149, Glutamate receptor, PTSD, Dipraglurant, Safety, Food and Drug Administration Amendments Act of 2007, Dystonia, Dyskinesia, Lists of diseases, L-DOPA, NAM, Janssen Pharmaceuticals, Protein, Drug discovery, American depositary receipt, Allosteric regulation, CEO, Pharmaceutical industry, Medical imaging

A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.

Key Points: 
  • A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • Addex remains committed to our allosteric modulator approach to drug discovery and development with two clinical trials currently ongoing.
  • Addex has been conducting a placebo-controlled Phase 2b/3 pivotal clinical trial of dipraglurant in PD-LID patients since June 2021.

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 19, 2022
SIX Swiss Exchange, Glutamic acid, Nasdaq, PAM, Glutamate (neurotransmitter), Psychosis, Therapy, Clinical trial, Blepharospasm, GABAB, Epilepsy, Neurodegeneration, ADX71149, Glutamate receptor, PTSD, Conference, Dystonia, Lists of diseases, Dyskinesia, L-DOPA, NAM, Janssen Pharmaceuticals, Protein, Drug discovery, American depositary receipt, Allosteric regulation, CEO, Pharmaceutical industry

Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.

Key Points: 
  • Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.
  • Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.
  • Mr. Dyer will be available for virtual one-on-one meetings throughout the conference.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Retrieved on: 
Friday, May 13, 2022
SIX Swiss Exchange, Glutamic acid, Nasdaq, PAM, Glutamate (neurotransmitter), Psychosis, Biology, Therapy, Clinical trial, Blepharospasm, GABAB, Epilepsy, Neurodegeneration, ADX71149, Glutamate receptor, PTSD, Conference, Dystonia, Lists of diseases, Dyskinesia, L-DOPA, NAM, Janssen Pharmaceuticals, Protein, Discovery, Drug discovery, American depositary receipt, Allosteric regulation, CEO, Pharmaceutical industry

Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.

Key Points: 
  • Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.
  • Mr. Dyer and Dr. Ltjens will be available for one-on-one meetings throughout the conference.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates with a focus in substance use disorder.

Addex Shareholders Approve All Resolutions at Annual General Meeting

Retrieved on: 
Tuesday, May 10, 2022
Dystonia, COVID-19, SIX Swiss Exchange, Epilepsy, Mission statement, Lists of diseases, American depositary receipt, Psychosis, 2003 Swiss Federal Council election, LR, NAM, Allosteric regulation, Annual report, Dyskinesia, Drug discovery, Federal Council, CHF, Clinical trial, AGM, ADX71149, L-DOPA, GABAB, Glutamate receptor, Commerce, Nasdaq, PAM, Glutamate (neurotransmitter), Association, BDO, PTSD, Blepharospasm, Annual general meeting, Therapy, Protein, Glutamic acid, Neurodegeneration, Janssen Pharmaceuticals, Pharmaceutical industry, Management, Swiss

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, May 10, 2022 Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM).
  • In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not attend the AGM in person.
  • Addex shareholders approved the 2021 annual report, the 2021 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote).
  • Addex shareholders approved the amendment of the articles of association concerning the authorized and conditional share capital of the company.

Addex Reports Q1 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
Dystonia, SIX Swiss Exchange, Epilepsy, Lists of diseases, American depositary receipt, Psychosis, NAM, Allosteric regulation, Dyskinesia, Drug discovery, Depreciation, CHF, Clinical trial, ADX71149, L-DOPA, GABAB, Glutamate receptor, Patent, Nasdaq, PAM, Glutamate (neurotransmitter), PTSD, Blepharospasm, Therapy, Protein, Research, Glutamic acid, Consultant, Neurodegeneration, Janssen Pharmaceuticals, Pharmaceutical industry, Income, Indivior

During the same period, staff costs increased by CHF 0.5 million of which CHF 0.3 million relate to higher share-based compensation costs and CHF 0.2 million relate to additional staff.

Key Points: 
  • During the same period, staff costs increased by CHF 0.5 million of which CHF 0.3 million relate to higher share-based compensation costs and CHF 0.2 million relate to additional staff.
  • R&D expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs.
  • Basic and diluted loss per share increased to CHF 0.15 for the first quarter 2022, compared to CHF 0.08 for the first quarter 2021.
  • Q1 2022 Consolidated Financial Statements:
    Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Addex to Present at the Swiss Biotech Day 2022

Retrieved on: 
Thursday, April 28, 2022
Blepharospasm, Drug discovery, Protein, CEO, Biotechnology, Georgia World Congress Center, Nasdaq, L-DOPA, ADX71149, GABAB, Therapy, SIX Swiss Exchange, Congress Center, Dystonia, Allosteric regulation, Clinical trial, Neurodegeneration, PAM, Janssen Pharmaceuticals, Glutamate (neurotransmitter), Epilepsy, PTSD, Lists of diseases, NAM, Dyskinesia, Glutamic acid, American depositary receipt, Glutamate receptor, Psychosis, CEST, Pharmaceutical industry

Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2022 taking place May 2 - 3, 2022, at the Congress Center in Basel, Switzerland.

Key Points: 
  • Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2022 taking place May 2 - 3, 2022, at the Congress Center in Basel, Switzerland.
  • In his live presentation, scheduled for 15:45 16:00 CEST, on May 2, 2022, in the Osaka/Samarkand room on the third floor, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference

Retrieved on: 
Monday, April 25, 2022
Protein, CEO, ADX71149, Nasdaq, Clinical trial, Allosteric regulation, PTSD, PDT, Glutamate (neurotransmitter), Lists of diseases, Psychosis, Dyskinesia, GABAB, Drug discovery, Dystonia, BST, SIX Swiss Exchange, PAM, Conference, Janssen Pharmaceuticals, EDT, Blepharospasm, Glutamate receptor, American depositary receipt, L-DOPA, NAM, Epilepsy, IR, Neurodegeneration, Glutamic acid, Therapy, Pharmaceutical industry

Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference taking place April 27 - 28, 2022.

Key Points: 
  • Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference taking place April 27 - 28, 2022.
  • A video of each presentation will be available for viewing on-demand by registered participants.
  • Mr Dyer will be available for virtual one-on-one meetings throughout both conferences.
  • For more information or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected] .